Clinical trial · Interventional
Intraluminal Peppermint Oil and Adenoma Detection Rate in Screening Colonoscopy
Intraluminal Peppermint Oil Can Increase Adenoma Detection Rate in Colon Cancer Screening Colonoscopy: A Double- Blinded Randomized Controlled Trial
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a prospective randomized placebo-controlled trial to evaluate the efficacy of peppermint oil spraying into the colonic lumen through the scope channel during screening colonoscopy. The primary outcome is to compare the colonic peristalsis between peppermint oil and placebo. The secondary outcomes compare the procedural time, polyp detection rate, adenoma detection rate, and adverse events.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Colonic Polyp | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Intraluminal peppermint oil | Drug | — | UNRESOLVED |
| Placebo | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Peppermint oil
- description
- 1.6% peppermint oil solution 50 ml(Peppermint oil plus simethicone and tween)
- interventionNames
- Drug: Intraluminal peppermint oil
- type
- PLACEBO_COMPARATOR
- label
- Placebo
- description
- Placebo solution 50ml(Simethicone plus tween)
- interventionNames
- Drug: Placebo
Primary outcomes (1)
- measure
- Adenoma detection rate(ADR)
- timeFrame
- During colonoscopy
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 100 Years
Show eligibility criteria text
Inclusion Criteria: \- Participants with age \> 18 years who attended for colorectal cancer screening colonoscopy. Exclusion Criteria: * Participants who had been colectomy * Participants who diagnosed of inflammatory bowel disease or polyposis syndrome. * Participants who had been took anti-spasmosic drugs prior to colonoscopy within 24 hours (Anticholibergic/Antimuscarinic : Hyoscine(Buscopan®), Dicyclomine(Berclomine®) or Smooth muscle relaxant : Mebeverine(Duspatin®,Colofac®), Pinaverium bromide(Dicetel®), Alverine(Meteospasmyl®), Peppermint oil(Colpermin®)) * Participants with Prothrombin time \> 3 second ULN, INR \> 1.5 or Platelet \< 50,000. * Pregnancy or breast feeding * Participants who cannot consent. * Participants who had history of peppermint oil allergy.
References
Publications (0)
Data not yet available